Evaluation of the Benefit of Ropeginterferon Treatment in Patients with Polycythemia Vera

Abstract

Results: Twenty-three patients (15 men and 8 women) with a median age of 57 years were enrolled, with 87.5% having the JAK617F mutation. Six patients had a history of thrombosis. Besremi was used as a first-line treatment in 11 patients and as a second-line treatment in 12 patients after Hydroxyurea administration. Complete hematologic response, defined by normalized blood counts and symptom resolution, was achieved in 3.46 ± 2.53 months in more than 50% of patients. One patient discontinued treatment, two did not achieve complete response, and four had less than 3 months of follow-up. After 6 months, the mean hematocrit was 44.17 ± 7.76 (p = 0.01), WBC 7.6 ± 3.92 x 1000/mmc (p = 0.02), and thrombocytosis significantly decreased in the first month (p = 0.02). Conclusions: Ropeginterferon treatment improved the quality of life for all patients, eliminating symptoms of cardiovascular and thrombotic complications. Approximately 60% of patients achieved complete hematologic response within the first 3 months.

Keywords

• policitemia vera
• myeloproliferative neoplasm
• ropeginterferon